Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration

Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndro...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanijcharoenkarn, Kristine, Lee, Frances Eun-Hyung, Martin, Lindsay, Shih, Jennifer, Sexton, Mary Elizabeth, Kuruvilla, Merin Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194535/
https://www.ncbi.nlm.nih.gov/pubmed/33989390
http://dx.doi.org/10.1093/cid/ciab448
Descripción
Sumario:Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2, focusing on diagnosis and management of allergic reactions.

Ejemplares similares